These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 16091562)
1. Managing lipid levels in diabetes beneficial but requires clinical judgment. Trubo R JAMA; 2005 Aug; 294(6):670. PubMed ID: 16091562 [No Abstract] [Full Text] [Related]
2. Should all diabetic patients be treated with a statin? Kamari Y; Bitzur R; Cohen H; Shaish A; Harats D Diabetes Care; 2009 Nov; 32 Suppl 2(Suppl 2):S378-83. PubMed ID: 19875585 [No Abstract] [Full Text] [Related]
3. Evidence-based medicine and the selection of lipid-lowering therapy in type 2 diabetes. Aguilar-Salinas CA; Mehta R; Gomez-Diaz RA Curr Diab Rep; 2012 Jun; 12(3):221-3. PubMed ID: 22451238 [No Abstract] [Full Text] [Related]
4. Therapy and clinical trials: fibrate therapy in type 2 diabetes - where are we now? Peter R; Reilly E; Anthony S Curr Opin Lipidol; 2010 Dec; 21(6):554-5. PubMed ID: 21206346 [No Abstract] [Full Text] [Related]
5. Controlled trial of effect of documented cardiovascular risk scores on prescribing. Hall LM; Jung RT; Leese GP BMJ; 2003 Feb; 326(7383):251-2. PubMed ID: 12560273 [No Abstract] [Full Text] [Related]
6. The role of fenofibrate in clinical practice. Zambon A; Cusi K Diab Vasc Dis Res; 2007 Sep; 4 Suppl 3():S15-20. PubMed ID: 17935056 [TBL] [Abstract][Full Text] [Related]
10. Vascular protection with fibroblast growth factor 21 in diabetes: its potential beyond glucose and lipid control. Liu MH Int J Cardiol; 2015 Nov; 199():403-4. PubMed ID: 26253049 [No Abstract] [Full Text] [Related]
11. [Lipid management--treatment goal and strategy]. Koshiyama H Nihon Rinsho; 2006 Nov; 64(11):2102-6. PubMed ID: 17087303 [TBL] [Abstract][Full Text] [Related]
12. Hyperlipidemia therapy in diabetes. Steil C Diabetes Educ; 1992; 18(2):105-9. PubMed ID: 1537237 [No Abstract] [Full Text] [Related]
13. Potential implications of the choice among three alternative treatment targets for apolipoprotein B100 in the management of patients with type 2 diabetes and chronic kidney disease. Boronat M; García-Cantón C; López-Ríos L; Quevedo V; Lorenzo DL; Batista F; Riaño M; Nóvoa FJ Diab Vasc Dis Res; 2014 Jan; 11(1):53-9. PubMed ID: 24254975 [TBL] [Abstract][Full Text] [Related]
14. Sugar, sugar. Wierzbicki AS Int J Clin Pract; 2013 Apr; 67(4):294-6. PubMed ID: 23521321 [No Abstract] [Full Text] [Related]
15. Statins and beyond: concurrent strategies for prevention of cardiovascular disease in patients with type 2 diabetes. Standl E Diab Vasc Dis Res; 2013 Mar; 10(2):99-114. PubMed ID: 22718811 [TBL] [Abstract][Full Text] [Related]
16. Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting. Bhushan R; Elkind-Hirsch KE; Bhushan M; Butler WJ; Duncan K; Marrioneaux O Diabetes Technol Ther; 2009 Jun; 11(6):353-9. PubMed ID: 19459763 [TBL] [Abstract][Full Text] [Related]
17. [Anti-diabetic therapy and cardiovascular risk]. Mannucci E G Ital Cardiol (Rome); 2014 Dec; 15(12 Suppl 2):3S. PubMed ID: 25623544 [No Abstract] [Full Text] [Related]
18. New drugs for the treatment of diabetes mellitus: part I: Thiazolidinediones and their evolving cardiovascular implications. McGuire DK; Inzucchi SE Circulation; 2008 Jan; 117(3):440-9. PubMed ID: 18212301 [No Abstract] [Full Text] [Related]
19. Combination lipid therapy in type 2 diabetes mellitus. Vergès B Expert Opin Pharmacother; 2011 Jun; 12(9):1393-403. PubMed ID: 21323502 [TBL] [Abstract][Full Text] [Related]
20. Fibrate use in diabetes: new concepts. Bloomgarden ZT; Drexler A J Diabetes; 2011 Mar; 3(1):1-2. PubMed ID: 21159144 [No Abstract] [Full Text] [Related] [Next] [New Search]